Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 154

1.

alpha-Adrenoceptor agonists for the treatment of vasovagal syncope: a meta-analysis of worldwide published data.

Liao Y, Li X, Zhang Y, Chen S, Tang C, Du J.

Acta Paediatr. 2009 Jul;98(7):1194-200. doi: 10.1111/j.1651-2227.2009.01289.x. Epub 2009 Apr 21.

PMID:
19397534
2.

[Meta-analysis of beta-adrenoceptor blockers for the treatment of vasovagal syncope].

Liao Y, Li XY, Zhang YW, Du JB.

Beijing Da Xue Xue Bao. 2008 Dec 18;40(6):603-9. Chinese.

3.

The efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope.

Qingyou Z, Junbao D, Chaoshu T.

J Pediatr. 2006 Dec;149(6):777-80.

PMID:
17137891
4.

Midodrine: a role in the management of neurocardiogenic syncope.

Ward CR, Gray JC, Gilroy JJ, Kenny RA.

Heart. 1998 Jan;79(1):45-9.

5.
6.

[Comparative efficacy and tolerance of atenolol and midodrine in patients with vasovagal syncopes].

Kuchinskaia EA, Pevzner AV, Vershuta EV, Al'bitskaia KV, Kheĭmets GI, Rogoza AN, Golitsyn SP.

Ter Arkh. 2006;78(4):64-8. Russian.

PMID:
16821426
7.

[Efficacy of midodrine hydrochloride in the treatment of children with vasovagal syncope].

Liu XY, Wang C, Wu LJ, Hu CY, Lin P, Li MX, Cui XL, Xie ZW.

Zhonghua Yi Xue Za Zhi. 2009 Jul 28;89(28):1951-4. Chinese.

PMID:
19950567
8.

Midodrine hydrochloride in the treatment of vasovagal syncope.

Mitro P, Trejbal D, Rybár AR.

Pacing Clin Electrophysiol. 1999 Nov;22(11):1620-4.

PMID:
10598965
9.

Usefulness of midodrine in patients with severely symptomatic neurocardiogenic syncope: a randomized control study.

Perez-Lugones A, Schweikert R, Pavia S, Sra J, Akhtar M, Jaeger F, Tomassoni GF, Saliba W, Leonelli FM, Bash D, Beheiry S, Shewchik J, Tchou PJ, Natale A.

J Cardiovasc Electrophysiol. 2001 Aug;12(8):935-8.

PMID:
11513446
10.

Strategy for the management of vasovagal syncope.

Bloomfield DM.

Drugs Aging. 2002;19(3):179-202. Review. Erratum in: Drugs Aging 2002;19(5):363.

PMID:
12027777
11.
12.

Effectiveness of midodrine treatment in patients with recurrent vasovagal syncope not responding to non-pharmacological treatment (STAND-trial).

Romme JJ, van Dijk N, Go-Schön IK, Reitsma JB, Wieling W.

Europace. 2011 Nov;13(11):1639-47. doi: 10.1093/europace/eur200. Epub 2011 Jul 13.

PMID:
21752826
13.

Randomized clinical trials of neurally mediated syncope.

Brignole M.

J Cardiovasc Electrophysiol. 2003 Sep;14(9 Suppl):S64-9. Review.

PMID:
12950522
14.

Efficacy and safety of midodrine hydrochloride in patients with refractory vasovagal syncope.

Samniah N, Sakaguchi S, Lurie KG, Iskos D, Benditt DG.

Am J Cardiol. 2001 Jul 1;88(1):A7, 80-3. No abstract available.

PMID:
11423066
15.
16.

The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope.

Gracie J, Newton JL, Norton M, Baker C, Freeston M.

Europace. 2006 Aug;8(8):636-43.

PMID:
16864617
17.

Long-term outcome of patients with vasovagal syncope.

Barón-Esquivias G, Errázquin F, Pedrote A, Cayuela A, Gómez S, Aguilera A, Campos A, Fernández M, Valle JI, Redondo M, Fernández JM, Martínez A, Burgos J, Martínez-Rubio A.

Am Heart J. 2004 May;147(5):883-9.

PMID:
15131546
18.

Neurocardiogenic syncope: latest pharmacological therapies.

Chen LY, Shen WK.

Expert Opin Pharmacother. 2006 Jun;7(9):1151-62. Review.

PMID:
16732702
19.

Pharmacologic approaches to therapy for vasovagal syncope.

Calkins H.

Am J Cardiol. 1999 Oct 21;84(8A):20Q-25Q. Review.

PMID:
10568557
20.

A case of neurally mediated syncope induced by laughter successfully treated with combination of propranolol and midodrine.

Amaki M, Kamide K, Takiuchi S, Niizuma S, Horio T, Kawano Y.

Int Heart J. 2007 Jan;48(1):123-7.

Supplemental Content

Support Center